Literature DB >> 31463208

Intramural hematoma and penetrating ulcer in the descending aorta: differences and similarities.

Arturo Evangelista1,2, Giuliana Maldonado2, Sergio Moral3, Gisela Teixido-Tura1, Angela Lopez1, Hug Cuellar4, Jose Rodriguez-Palomares1.   

Abstract

Acute aortic syndromes include a variety of overlapping clinical and anatomic diseases. Intramural hematoma (IMH), penetrating atherosclerotic ulcer (PAU), and aortic dissection can occur as isolated processes or can be found in association. All these entities are potentially life threatening, so prompt diagnosis and treatment is of paramount importance. IMH and PAU affect patients with atherosclerotic risk factors and are located in the descending aorta in 60-70% of cases. IMH diagnosis can be correctly made in most cases. Aortic ulcer is a morphologic entity which comprises several entities-the differential diagnosis includes PAU, focal intimal disruptions (FID) in the context of IMH evolution and ulcerated atherosclerotic plaque. The pathophysiologic mechanism, evolution and prognosis differ somewhat between these entities. However, most PAU are diagnosed incidentally outside the acute phase. Persistent pain despite medical treatment, hemodynamic instability, maximum aortic diameter (MAD) >55 mm, significant periaortic hemorrhage and FID in acute phase of IMH are predictors of acute-phase mortality. In these cases, TEVAR or open surgery should be considered. In non-complicated IMH or PAU, without significant aortic enlargement, strict control of cardiovascular risk factors and frequent follow-up imaging appears to be a safe management strategy.

Entities:  

Keywords:  Intramural hematoma (IMH); acute aortic syndrome (AAS); aortic ulcer (AU); focal intimal disruption; penetrating atherosclerotic ulcer (PAU)

Year:  2019        PMID: 31463208      PMCID: PMC6687957          DOI: 10.21037/acs.2019.07.05

Source DB:  PubMed          Journal:  Ann Cardiothorac Surg        ISSN: 2225-319X


  8 in total

Review 1.  Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes.

Authors:  Eduardo Bossone; Kim A Eagle
Journal:  Nat Rev Cardiol       Date:  2020-12-22       Impact factor: 32.419

2.  Management of penetrating aortic ulcer and intramural hematoma in the thoracic aorta.

Authors:  David L Warner; Castigliano M Bhamidipati; Cherrie Z Abraham
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2022-03-09

3.  Transesophageal Ultrasound Guidance for Endovascular Interventions on the Aorta.

Authors:  Mireya Castro-Verdes; Xun Yuan; Andreas Mitsis; Wei Li; Christoph A Nienaber
Journal:  Aorta (Stamford)       Date:  2022-05-31

4.  Endovascular Treatment of Spontaneous and Isolated Infrarenal Acute Aortic Syndrome with Unibody Aortic Stent-Grafts.

Authors:  Felice Pecoraro; Ettore Dinoto; Domenico Mirabella; Francesca Ferlito; Arduino Farina; David Pakeliani; Mario Lachat; Francesca Urso; Guido Bajardi
Journal:  World J Surg       Date:  2020-09-03       Impact factor: 3.352

Review 5.  Demystifying penetrating atherosclerotic ulcer of aorta: unrealised tyrant of senile aortic changes.

Authors:  Rahul Dev; Khorwal Gitanjali; Darbari Anshuman
Journal:  J Cardiovasc Thorac Res       Date:  2021-01-30

6.  A penetrating atherosclerotic ulcer rapidly growing into a saccular aortic aneurysm during treatment of leukaemia: a case report.

Authors:  Shinsuke Takeuchi; Nobuyuki Takayama; Kyoko Soejima; Hideaki Yoshino
Journal:  Eur Heart J Case Rep       Date:  2021-07-12

7.  Endovascular treatment of penetrating atherosclerotic ulcers of the arch and thoracic aorta: In-hospital and 5-year outcomes.

Authors:  Giacomo Murana; Luca Di Marco; Mariafrancesca Fiorentino; Francesco Buia; Giorgia Brillanti; Luigi Lovato; Davide Pacini
Journal:  JTCVS Open       Date:  2022-04-04

8.  Aortic injury caused by esophageal foreign body-case reports of 3 patients and literature review.

Authors:  Liping Zeng; Wenbo Shu; Honghai Ma; Jian Hu
Journal:  Medicine (Baltimore)       Date:  2020-06-26       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.